{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:40:29Z","timestamp":1790746829671,"version":"4.1.0"},"reference-count":187,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Primary immunodeficiencies (PID) are rare, complex diseases that can be characterised by a spectrum of phenotypes, from increased susceptibility to infections to autoimmunity, allergy, auto-inflammatory diseases and predisposition to malignancy. With the introduction of genetic testing in these patients and wider use of next-Generation sequencing techniques, a higher number of pathogenic genetic variants and conditions have been identified, allowing the development of new, targeted treatments in PID. The concept of precision medicine, that aims to tailor the medical interventions to each patient, allows to perform more precise diagnosis and more importantly the use of treatments directed to a specific defect, with the objective to cure or achieve long-term remission, minimising the number and type of side effects. This approach takes particular importance in PID, considering the nature of causative defects, disease severity, short- and long-term complications of disease but also of the available treatments, with impact in life-expectancy and quality of life. In this review we revisit how this approach can or is already being implemented in PID and provide a summary of the most relevant treatments applied to specific diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1029560","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T09:59:30Z","timestamp":1670493570000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Precision medicine: The use of tailored therapy in primary immunodeficiencies"],"prefix":"10.3389","volume":"13","author":[{"given":"Marta Valente","family":"Pinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Farela","family":"Neves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00391-2017","article-title":"What is precision medicine","volume":"50","author":"Konig","year":"2017","journal-title":"Eur Respir J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1042\/ETLS20190197","article-title":"The future of precision medicine: Towards a more predictive personalized medicine","volume":"4","author":"Elemento","year":"2020","journal-title":"Emerg Top Life Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s41232-021-00159-6","article-title":"Inborn errors of immunity-recent advances in research on the pathogenesis","volume":"41","author":"Yamashita","year":"2021","journal-title":"Inflammation Regener"},{"key":"B4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s10875-020-00758-x","article-title":"Holland SM et al: Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification","volume":"40","author":"Bousfiha","year":"2020","journal-title":"J Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1542\/peds.9.6.722","article-title":"Agammaglobulinemia","volume":"9","author":"Bruton","year":"1952","journal-title":"Pediatrics"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(62)80092-4","article-title":"A decade with agammaglobulinemia","volume":"60","author":"Bruton","year":"1962","journal-title":"J Pediatr"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197009172831211","article-title":"Classification of the primary immune deficiencies: WHO recommendation","volume":"283","author":"Fudenberg","year":"1970","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.12.1347","article-title":"International union of immunological societies primary immunodeficiency diseases classification c: Primary immunodeficiency diseases: An update from the international union of immunological societies primary immunodeficiency diseases classification committee meeting in Budapest, 2005","volume":"117","author":"Notarangelo","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01352-z","article-title":"The 2022 update of IUIS phenotypical classification for human inborn errors of immunity","volume":"42","author":"Bousfiha","year":"2022","journal-title":"J Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000689","article-title":"Primary immune regulatory disorders: a growing universe of immune dysregulation","volume":"20","author":"Chan","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01378-8","article-title":"EBMT\/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity","volume":"56","author":"Lankester","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddz170","article-title":"Gene therapy for primary immunodeficiency","volume":"28","author":"Booth","year":"2019","journal-title":"Hum Mol Genet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.01.004","article-title":"Targeted strategies directed at the molecular defect: Toward precision medicine for select primary immunodeficiency disorders","volume":"139","author":"Notarangelo","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201707573","article-title":"Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: Paving the road for the next generation of advanced therapy medicinal products","volume":"9","author":"Aiuti","year":"2017","journal-title":"EMBO Mol Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.608653","article-title":"Immune reconstitution after gene therapy approaches in patients with X-linked severe combined immunodeficiency disease","volume":"11","author":"Blanco","year":"2020","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.DMIH2-0026-2016","article-title":"Overview of infections in the immunocompromised host","volume":"4","author":"Dropulic","year":"2016","journal-title":"Microbiol Spectr"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2174\/138161209788682325","article-title":"The roles of antimicrobial peptides in innate host defense","volume":"15","author":"Diamond","year":"2009","journal-title":"Curr Pharm Des"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jped.2020.10.005","article-title":"Treatment of patients with immunodeficiency: Medication, gene therapy, and transplantation","author":"Segundo","year":"2021","journal-title":"J Pediatr (Rio J)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00373","article-title":"Universal newborn screening for severe combined immunodeficiency (SCID)","volume":"7","author":"van der Burg","year":"2019","journal-title":"Front Pediatr"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12729","article-title":"Newborn screening for severe combined immunodeficiency and T-cell lymphopenia","volume":"287","author":"Puck","year":"2019","journal-title":"Immunol Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00481","article-title":"Hematopoietic stem cell transplantation for severe combined immunodeficiency (SCID)","volume":"7","author":"Haddad","year":"2019","journal-title":"Front Pediatr"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-017-0373-y","article-title":"How we manage adenosine deaminase-deficient severe combined immune deficiency (ADA SCID)","volume":"37","author":"Kohn","year":"2017","journal-title":"J Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1995.6.6-709","article-title":"Gene therapy in Europe","volume":"6","author":"Bordignon","year":"1995","journal-title":"Hum Gene Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805817","article-title":"Gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"360","author":"Aiuti","year":"2009","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.648951","article-title":"Gene therapies for primary immune deficiencies","volume":"12","author":"Kohn","year":"2021","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.12.022","article-title":"Gene therapy for adenosine deaminase deficiency: A comprehensive evaluation of short- and medium-term safety","volume":"26","author":"Cicalese","year":"2018","journal-title":"Mol Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J Clin Invest"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1216","article-title":"Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration","volume":"24","author":"Montini","year":"2006","journal-title":"Nat Biotechnol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-020-00298-5","article-title":"Gene therapy using haematopoietic stem and progenitor cells","volume":"22","author":"Ferrari","year":"2021","journal-title":"Nat Rev Genet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-616003","article-title":"Faster T-cell development following gene therapy compared with haploidentical HSCT in the treatment of SCID-X1","volume":"125","author":"Touzot","year":"2015","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815408","article-title":"Lentiviral gene therapy combined with low-dose busulfan in infants with SCID-X1","volume":"380","author":"Mamcarz","year":"2019","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2016.064","article-title":"Lentivirus mediated correction of Artemis-deficient severe combined immunodeficiency","volume":"28","author":"Punwani","year":"2017","journal-title":"Hum Gene Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.03.016","article-title":"Successful preclinical development of gene therapy for recombinase-activating gene-1-Deficient SCID","volume":"17","author":"Garcia-Perez","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/MOH.0000000000000696","article-title":"Congenital neutropenia: Disease models guiding new treatment strategies","volume":"29","author":"Touw","year":"2022","journal-title":"Curr Opin Hematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116712","article-title":"Extended genetic testing in severe congenital neutropenia may identify mutations that inform therapy","volume":"132","author":"Link","year":"2018","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129844","article-title":"Response to high dose G-CSF treatment (20\u00b5g\/kg\/d or higher) of patients with congenital neutropenia: An analysis by the scnir in Europe","volume":"134","author":"Zeidler","year":"2019","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500861","article-title":"G-CSF and GM-CSF in neutropenia","volume":"195","author":"Mehta","year":"2015","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.clim.2018.03.005","article-title":"Long term outcome of eight patients with type 1 leukocyte adhesion deficiency (LAD-1): Not only infections, but high risk of autoimmune complications","volume":"191","author":"De Rose","year":"2018","journal-title":"Clin Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00436","article-title":"The evidence for allogeneic hematopoietic stem cell transplantation for congenital neutrophil disorders: A comprehensive review by the inborn errors working party group of the EBMT","volume":"7","author":"Bakhtiar","year":"2019","journal-title":"Front Pediatr"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.08.004","article-title":"CRISPR-Cas9-Mediated ELANE mutation correction in hematopoietic stem and progenitor cells to treat severe congenital neutropenia","volume":"28","author":"Tran","year":"2020","journal-title":"Mol Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-020-08800-x","article-title":"Chronic granulomatous disease: A comprehensive review","volume":"61","author":"Yu","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1093\/jpids\/piy007","article-title":"Considerations in the diagnosis of chronic granulomatous disease","volume":"7","author":"Yu","year":"2018","journal-title":"J Pediatr Infect Dis Soc"},{"key":"B44","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1476-9433-5-4","article-title":"Chronic granulomatous disease; fundamental stages in our understanding of CGD","volume":"5","author":"Assari","year":"2006","journal-title":"Med Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(66)90238-8","article-title":"Fatal granulomatous disease of childhood","volume":"287","author":"Holmes","year":"1966","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196805022781802","article-title":"Defective polymorphonuclear-leukocyte function and chronic granulomatous disease in two female children","volume":"278","author":"Quie","year":"1968","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cytogfr.2018.04.001","article-title":"The tolerogenic role of IFN-gamma","volume":"41","author":"Rozman","year":"2018","journal-title":"Cytokine Growth Factor Rev"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1086\/422993","article-title":"Long-term interferon-gamma therapy for patients with chronic granulomatous disease","volume":"39","author":"Marciano","year":"2004","journal-title":"Clin Infect Dis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199102213240801","article-title":"A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease","volume":"324","year":"1991","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1172\/JCI113153","article-title":"Recombinant interferon gamma augments phagocyte superoxide production and X-chronic granulomatous disease gene expression in X-linked variant chronic granulomatous disease","volume":"80","author":"Ezekowitz","year":"1987","journal-title":"J Clin Invest"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.6.3.420-424.1999","article-title":"Gamma interferon treatment of patients with chronic granulomatous disease is associated with augmented production of nitric oxide by polymorphonuclear neutrophils","volume":"6","author":"Ahlin","year":"1999","journal-title":"Clin Diagn Lab Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.11.3548","article-title":"Interferon-gamma improves splicing efficiency of CYBB gene transcripts in an interferon-responsive variant of chronic granulomatous disease due to a splice site consensus region mutation","volume":"95","author":"Condino-Neto","year":"2000","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.00327","article-title":"Cellular therapies in chronic granulomatous disease","volume":"8","author":"Gungor","year":"2020","journal-title":"Front Pediatr"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13402","article-title":"Outcome of chronic granulomatous disease - conventional treatment vs stem cell transplantation","volume":"32","author":"Dedieu","year":"2021","journal-title":"Pediatr Allergy Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0735-5","article-title":"Lentiviral gene therapy for X-linked chronic granulomatous disease","volume":"26","author":"Kohn","year":"2020","journal-title":"Nat Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-020-0164-6","article-title":"Lentiviral gene therapy rescues p47(phox) chronic granulomatous disease and the ability to fight salmonella infection in mice","volume":"27","author":"Schejtman","year":"2020","journal-title":"Gene Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03047","article-title":"IRF and STAT transcription factors - from basic biology to roles in infection, protective immunity, and primary immunodeficiencies","volume":"9","author":"Mogensen","year":"2018","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: From bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2012.04.011","article-title":"Inborn errors of human STAT1: Allelic heterogeneity governs the diversity of immunological and infectious phenotypes","volume":"24","author":"Boisson-Dupuis","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.654406","article-title":"Clinical relevance of gain- and loss-of-Function germline mutations in STAT1: A systematic review","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s10875-018-0519-6","article-title":"Utility of ruxolitinib in a child with chronic mucocutaneous candidiasis caused by a novel STAT1 gain-of-Function mutation","volume":"38","author":"Bloomfield","year":"2018","journal-title":"J Clin Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"ofx202","DOI":"10.1093\/ofid\/ofx202","article-title":"Risks of ruxolitinib in STAT1 gain-of-Function-Associated severe fungal disease","volume":"4","author":"Zimmerman","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90187-I","article-title":"A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia","volume":"89","author":"Wetzler","year":"1990","journal-title":"Am J Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1080\/21678707.2017.1375403","article-title":"Pathogenesis, diagnosis and therapeutic strategies in WHIM syndrome immunodeficiency","volume":"5","author":"Heusinkveld","year":"2017","journal-title":"Expert Opin Orphan Drugs"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/ng1149","article-title":"Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease","volume":"34","author":"Hernandez","year":"2003","journal-title":"Nat Genet"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808575","article-title":"Plerixafor for the treatment of WHIM syndrome","volume":"380","author":"McDermott","year":"2019","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-019-00665-w","article-title":"WHIM syndrome: from pathogenesis towards personalized medicine and cure","volume":"39","author":"Heusinkveld","year":"2019","journal-title":"J Clin Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1182\/blood.2020007197","article-title":"Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome","volume":"136","author":"Dale","year":"2020","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12726","article-title":"Early-onset inflammatory bowel disease as a model disease to identify key regulators of immune homeostasis mechanisms","volume":"287","author":"Pazmandi","year":"2019","journal-title":"Immunol Rev"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.5223\/pghn.2020.23.5.411","article-title":"Very early-onset inflammatory bowel disease: A challenging field for pediatric gastroenterologists","volume":"23","author":"Arai","year":"2020","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907206","article-title":"Murugan d et al: Inflammatory bowel disease and mutations affecting the interleukin-10 receptor","volume":"361","author":"Glocker","year":"2009","journal-title":"N Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.03.021","article-title":"A systematic review of monogenic inflammatory bowel disease","volume":"20","author":"Nambu","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2018.12.001","article-title":"TTC7A: Steward of intestinal health","volume":"7","author":"Jardine","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.jaci.2008.08.026","article-title":"Allogeneic transplantation successfully corrects immune defects, but not susceptibility to colitis, in a patient with nuclear factor-kappaB essential modulator deficiency","volume":"122","author":"Pai","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.08.055","article-title":"Interleukin 1beta mediates intestinal inflammation in mice and patients with interleukin 10 receptor deficiency","volume":"151","author":"Shouval","year":"2016","journal-title":"Gastroenterology"},{"key":"B76","article-title":"ESID registry:working definitions for clinical diagnosis of PID","volume-title":"ESID registry:working definitions for clinical diagnosis of PID","year":"2019"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000929","article-title":"Current genetic landscape in common variable immune deficiency","volume":"135","author":"Abolhassani","year":"2020","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1663","article-title":"AUTOIMMUNE DISEASE. patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy","volume":"349","author":"Lo","year":"2015","journal-title":"Science"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.03.017","article-title":"PI3K pathway defects leading to immunodeficiency and immune dysregulation","volume":"143","author":"Nunes-Santos","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00369","article-title":"Activated PI3 kinase delta syndrome: From genetics to therapy","volume":"9","author":"Michalovich","year":"2018","journal-title":"Front Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02043","article-title":"The treatment of activated PI3Kdelta syndrome","volume":"9","author":"Coulter","year":"2018","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.93","article-title":"PI3Kdelta and primary immunodeficiencies","volume":"16","author":"Lucas","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-801191","article-title":"Cabanski m et al: Effective \"activated PI3Kdelta syndrome\"-targeted therapy with the PI3Kdelta inhibitor leniolisib","volume":"130","author":"Rao","year":"2017","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12964-017-0177-y","article-title":"The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells","volume":"15","author":"Seif","year":"2017","journal-title":"Cell Commun Signal"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2021.03.003","article-title":"Germline STAT3 gain-of-function mutations in primary immunodeficiency: Impact on the cellular and clinical phenotype","volume":"44","author":"Faletti","year":"2021","journal-title":"BioMed J"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2020.04.001","article-title":"Precision therapy for the treatment of primary immunodysregulatory diseases","volume":"40","author":"Chellapandian","year":"2020","journal-title":"Immunol Allergy Clin North Am"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-610592","article-title":"STAT3: Too much may be worse than not enough","volume":"125","author":"Haddad","year":"2015","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-00975-y","article-title":"Suzuki K Et al: Clinical and immunological heterogeneity in Japanese patients with gain-of-Function variants in STAT3","volume":"41","author":"Tanita","year":"2021","journal-title":"J Clin Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-570101","article-title":"Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3","volume":"125","author":"Haapaniemi","year":"2015","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-602763","article-title":"Topcagic n et al: Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations","volume":"125","author":"Milner","year":"2015","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3390\/cancers6020897","article-title":"STAT3 target genes relevant to human cancers","volume":"6","author":"Carpenter","year":"2014","journal-title":"Cancers (Basel)"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.07.020","article-title":"Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations","volume":"142","author":"Forbes","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00864-w","article-title":"Ruxolitinib controls lymphoproliferation and diabetes in a STAT3-GOF patient","volume":"40","author":"Wegehaupt","year":"2020","journal-title":"J Clin Immunol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1053\/j.gastro.2018.11.065","article-title":"Efficacy of ruxolitinib therapy in a patient with severe enterocolitis associated with a STAT3 gain-of-Function mutation","volume":"156","author":"Parlato","year":"2019","journal-title":"Gastroenterology"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.2337\/db16-1250","article-title":"Repurposed JAK1\/JAK2 inhibitor reverses established autoimmune insulitis in NOD mice","volume":"66","author":"Trivedi","year":"2017","journal-title":"Diabetes"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2006.09.018","article-title":"Stattic: a small-molecule inhibitor of STAT3 activation and dimerization","volume":"13","author":"Schust","year":"2006","journal-title":"Chem Biol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M107527200","article-title":"Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation","volume":"276","author":"Turkson","year":"2001","journal-title":"J Biol Chem"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.261.3.3","article-title":"Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity","volume":"3","author":"Turkson","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"B99","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","article-title":"Targeting STAT3 in cancer immunotherapy","volume":"19","author":"Zou","year":"2020","journal-title":"Mol Cancer"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80721-7","article-title":"Pettersson T et al: Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes","volume":"97","author":"McDermott","year":"1999","journal-title":"Cell"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00497","article-title":"Toward an inclusive, congruent, and precise definition of autoinflammatory diseases","volume":"8","author":"Wekell","year":"2017","journal-title":"Front Immunol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/intimm\/dxx020","article-title":"A clinical update on inflammasomopathies","volume":"29","author":"Sonmez","year":"2017","journal-title":"Int Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201602089","article-title":"The cell biology of inflammasomes: Mechanisms of inflammasome activation and regulation","volume":"213","author":"Sharma","year":"2016","journal-title":"J Cell Biol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41421-020-0167-x","article-title":"Inflammasome activation and regulation: toward a better understanding of complex mechanisms","volume":"6","author":"Zheng","year":"2020","journal-title":"Cell Discov"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00873","article-title":"The role of interferons in inflammation and inflammasome activation","volume":"8","author":"Kopitar-Jerala","year":"2017","journal-title":"Front Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-019-00638-z","article-title":"CAPS and NLRP3","volume":"39","author":"Booshehri","year":"2019","journal-title":"J Clin Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/art.39763","article-title":"The phenotype and genotype of mevalonate kinase deficiency: A series of 114 cases from the eurofever registry","volume":"68","author":"Ter Haar","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01150","article-title":"Management of mevalonate kinase deficiency: A pediatric perspective","volume":"11","author":"Jeyaratnam","year":"2020","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03958.x","article-title":"Rilonacept and canakinumab","volume":"71","author":"Dubois","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201708689","article-title":"Tranilast directly targets NLRP3 to treat inflammasome-driven diseases","volume":"10","author":"Huang","year":"2018","journal-title":"EMBO Mol Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012-3344","article-title":"Severe early-onset colitis revealing mevalonate kinase deficiency","volume":"132","author":"Levy","year":"2013","journal-title":"Pediatrics"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3212","article-title":"Guarding the frontiers: the biology of type III interferons","volume":"16","author":"Wack","year":"2015","journal-title":"Nat Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.631329","article-title":"Type I interferonopathies in children: An overview","volume":"9","author":"d'Angelo","year":"2021","journal-title":"Front Pediatr"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00633-9","article-title":"The type I interferonopathies: 10 years on","volume":"15","author":"Crow","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/nri3850","article-title":"Aicardi-goutieres syndrome and the type I interferonopathies","volume":"15","author":"Crow","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.04.046","article-title":"Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome","volume":"62","author":"Torrelo","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00927","article-title":"CANDLE syndrome as a paradigm of proteasome-related autoinflammation","volume":"8","author":"Torrelo","year":"2017","journal-title":"Front Immunol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12969-015-0035-7","article-title":"Severe immune dysregulation with neurological impairment and minor bone changes in a child with spondyloenchondrodysplasia due to two novel mutations in the ACP5 gene","volume":"13","author":"Girschick","year":"2015","journal-title":"Pediatr Rheumatol Online J"},{"key":"B120","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11926-020-00909-4","article-title":"Type I interferonopathies: from a novel concept to targeted therapeutics","volume":"22","author":"Melki","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00517-9","article-title":"Efficacy and safety of janus kinase inhibitors in type I interferon-mediated monogenic autoinflammatory disorders: A scoping review","volume":"11","author":"Gomez-Arias","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B122","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1182\/blood-2017-11-814244","article-title":"Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis","volume":"132","author":"Chinn","year":"2018","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2020.04.003","article-title":"Hemophagocytic lymphohistiocytosis: Lessons learned from the dark side","volume":"40","author":"Chellapandian","year":"2020","journal-title":"Immunol Allergy Clin North Am"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Rosee","year":"2019","journal-title":"Blood"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124477","article-title":"Alemtuzumab as first line treatment in children with familial lymphohistiocytosis","volume":"134","author":"Fischer","year":"2019","journal-title":"Blood"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.660520","article-title":"Evolution of our understanding of XIAP deficiency","volume":"9","author":"Mudde","year":"2021","journal-title":"Front Pediatr"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00666","article-title":"X-Linked lymphoproliferative disease type 1: A clinical and molecular perspective","volume":"9","author":"Panchal","year":"2018","journal-title":"Front Immunol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00353","article-title":"Inborn errors of immunity with immune dysregulation: From bench to bedside","volume":"7","author":"Delmonte","year":"2019","journal-title":"Front Pediatr"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1159\/000503997","article-title":"Targeted therapy with biologicals and small molecules in primary immunodeficiencies","volume":"29","author":"Delmonte","year":"2020","journal-title":"Med Princ Pract"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01236-2","article-title":"A case of XIAP deficiency successfully managed with tadekinig Alfa (rhIL-18BP)","volume":"42","author":"Geerlinks","year":"2022","journal-title":"J Clin Immunol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.jaci.2017.11.050","article-title":"T-Cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations","volume":"142","author":"Ghosh","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.242","article-title":"Perforin gene transfer into hematopoietic stem cells improves immune dysregulation in murine models of perforin deficiency","volume":"23","author":"Carmo","year":"2015","journal-title":"Mol Ther"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017012088","article-title":"Gene transfer into hematopoietic stem cells reduces HLH manifestations in a murine model of Munc13-4 deficiency","volume":"1","author":"Soheili","year":"2017","journal-title":"Blood Adv"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-445858","article-title":"SAP gene transfer restores cellular and humoral immune function in a murine model of X-linked lymphoproliferative disease","volume":"121","author":"Rivat","year":"2013","journal-title":"Blood"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.692219","article-title":"The use of biologic modifiers as a bridge to hematopoietic cell transplantation in primary immune regulatory disorders","volume":"12","author":"Arnold","year":"2021","journal-title":"Front Immunol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.717388","article-title":"Emerging place of JAK inhibitors in the treatment of inborn errors of immunity","volume":"12","author":"Hadjadj","year":"2021","journal-title":"Front Immunol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12969-019-0322-9","article-title":"Disease course and treatment effects of a JAK inhibitor in a patient with CANDLE syndrome","volume":"17","author":"Boyadzhiev","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.614704","article-title":"Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis","volume":"12","author":"Keenan","year":"2021","journal-title":"Front Immunol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.12.017","article-title":"Mechanism-based precision therapy for the treatment of primary immunodeficiency and primary immunodysregulatory diseases","volume":"7","author":"Leiding","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2021.2023173","article-title":"The role of TNF-\u03b1 and anti-TNF-\u03b1 agents in the immunopathogenesis and management of immune dysregulation in primary immunodeficiency diseases","volume":"44","author":"Abubakar","year":"2022","journal-title":"Immunopharmacol Immunotoxicology"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911326","article-title":"Putti MC et al: Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp070449","article-title":"Tocilizumab: the first interleukin-6-receptor inhibitor","volume":"65","author":"Sebba","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.6.17815","article-title":"Discovery and mechanism of ustekinumab: A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders","volume":"3","author":"Benson","year":"2011","journal-title":"MAbs"},{"key":"B145","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4161\/mabs.2.1.10328","article-title":"Canakinumab","volume":"2","author":"Dhimolea","year":"2010","journal-title":"MAbs"},{"key":"B146","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.berh.2017.12.001","article-title":"Periodic fever syndromes","volume":"31","author":"Lachmann","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.reumae.2011.08.004","article-title":"Abatacept mechanism of action: Concordance with its clinical profile","volume":"8","author":"Herrero-Beaumont","year":"2012","journal-title":"Reumatolog\u00eda Cl\u00ednica (English Edition)"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: Mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2006.05.007","article-title":"Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab","volume":"44","author":"Carnahan","year":"2007","journal-title":"Mol Immunol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000431","article-title":"Precision medicine in the treatment of primary immunodeficiency diseases","volume":"18","author":"Leiding","year":"2018","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.611690","article-title":"The role of mTOR inhibitors in hematologic disease: From bench to bedside","volume":"10","author":"Feng","year":"2020","journal-title":"Front Oncol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: Current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"B153","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B155","doi-asserted-by":"publisher","first-page":"O31","DOI":"10.1186\/1546-0096-13-S1-O31","article-title":"Preliminary response to janus kinase inhibition with baricitinib in chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures (CANDLE)","volume":"13","author":"Montealegre","year":"2015","journal-title":"Pediatr Rheumatol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01257-x","article-title":"Kanderova V et al: Impact of JAK inhibitors in pediatric patients with STAT1 gain of function (GOF) mutations-10 children and review of the literature","volume":"42","author":"Deya-Martinez","year":"2022","journal-title":"J Clin Immunol"},{"key":"B157","article-title":"Full prescribing information FDA","volume-title":"JAKAVI","year":""},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00914-3","article-title":"Life-saving, dose-adjusted, targeted therapy in a patient with a STAT3 gain-of-Function mutation","volume":"41","author":"Sarfati","year":"2021","journal-title":"J Clin Immunol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1182\/blood-2016-02-700013","article-title":"Therapeutic effect of JAK1\/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice","volume":"128","author":"Maschalidi","year":"2016","journal-title":"Blood"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00460","article-title":"Drugs for autoimmune inflammatory diseases: From small molecule compounds to anti-TNF biologics","volume":"8","author":"Li","year":"2017","journal-title":"Front Pharmacol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-014-0079-3","article-title":"Infliximab for treatment of granulomatous disease in patients with common variable immunodeficiency","volume":"34","author":"Franxman","year":"2014","journal-title":"J Clin Immunol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"102872","DOI":"10.1016\/j.autrev.2021.102872","article-title":"Inflammatory bowel disease in primary immunodeficiency disorders is a heterogeneous clinical entity requiring an individualized treatment strategy: A systematic review","volume":"20","author":"Both","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2020.04.013","article-title":"Infliximab induces clinical resolution of sacroiliitis that coincides with increased circulating FOXP3(+) T cells in a patient with IPEX syndrome","volume":"87","author":"Boschetti","year":"2020","journal-title":"Joint Bone Spine"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.01.034","article-title":"Etanercept treatment of cutaneous granulomas in common variable immunodeficiency","volume":"117","author":"Lin","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1089\/ped.2019.1036","article-title":"Etanercept for the treatment of chronic arthritis related to chronic granulomatous disease: A case","volume":"32","author":"Balci","year":"2019","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01905","article-title":"Neutralizing activity of anti-interferon-gamma autoantibodies in adult-onset immunodeficiency is associated with their binding domains","volume":"10","author":"Yasamut","year":"2019","journal-title":"Front Immunol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15133","article-title":"Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: A pharmacometric model-based approach","volume":"88","author":"Jacqmin","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.012","article-title":"Interleukin-1 and related cytokines in the regulation of inflammation and immunity","volume":"50","author":"Mantovani","year":"2019","journal-title":"Immunity"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.619257","article-title":"IL-1 inhibitors in the treatment of monogenic periodic fever syndromes: From the past to the future perspectives","volume":"11","author":"Malcova","year":"2020","journal-title":"Front Immunol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1002\/art.20303","article-title":"Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial","volume":"50","author":"Nishimoto","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B171","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12865-021-00411-1","article-title":"Efficacy of tocilizumab therapy in a patient with severe pancytopenia associated with a STAT3 gain-of-function mutation","volume":"22","author":"Wang","year":"2021","journal-title":"BMC Immunol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00235","article-title":"Arthritis in two patients with partial recombination activating gene deficiency","volume":"7","author":"Wu","year":"2019","journal-title":"Front Pediatr"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.10.022","article-title":"Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition","volume":"139","author":"Canna","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612197","article-title":"Interleukin-12 and interleukin-23 blockade in leukocyte adhesion deficiency type 1","volume":"376","author":"Moutsopoulos","year":"2017","journal-title":"N Engl J Med"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.02.055","article-title":"Takagi m et al: Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects","volume":"142","author":"Schwab","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1097\/PG9.0000000000000099","article-title":"CTLA-4 haploinsufficiency presenting as extensive enteropathy in a patient with very early onset inflammatory bowel disease","volume":"2","author":"Tran","year":"2021","journal-title":"JPGN Rep"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.08.036","article-title":"Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4","volume":"137","author":"Lee","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: Advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat Rev Drug Discovery"},{"key":"B179","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1365-2141.2011.08880.x","article-title":"Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: A retrospective multicentre study on 33 patients","volume":"155","author":"Gobert","year":"2011","journal-title":"Br J Haematol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211028653","article-title":"10 years of belimumab experience: What have we learnt","volume":"30","author":"Levy","year":"2021","journal-title":"Lupus"},{"key":"B181","doi-asserted-by":"publisher","first-page":"8955","DOI":"10.3390\/ijms22168955","article-title":"The proteasome inhibitor bortezomib induces apoptosis and activation in gel-filtered human platelets","volume":"22","author":"Ghansah","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.273","article-title":"Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia","volume":"30","author":"Rogers","year":"2016","journal-title":"Leukemia"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018020883","article-title":"Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation","volume":"2","author":"Schuetz","year":"2018","journal-title":"Blood Adv"},{"key":"B184","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3109\/08830185.2014.933957","article-title":"mTOR signaling in T cell immunity and autoimmunity","volume":"34","author":"Liu","year":"2015","journal-title":"Int Rev Immunol"},{"key":"B185","first-page":"15","article-title":"mTOR inhibitors at a glance","volume":"7","author":"Zheng","year":"2015","journal-title":"Mol Cell Pharmacol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2019000051","article-title":"Primary immunodeficiencies: novel genes and unusual presentations","volume":"2019","author":"Notarangelo","year":"2019","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2892","article-title":"A general framework for estimating the relative pathogenicity of human genetic variants","volume":"46","author":"Kircher","year":"2014","journal-title":"Nat Genet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1029560\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T09:59:36Z","timestamp":1670493576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1029560\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":187,"alternative-id":["10.3389\/fimmu.2022.1029560"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1029560","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]},"article-number":"1029560"}}